Logo image of GNPX

GENPREX INC (GNPX) Stock Fundamental Analysis

USA - NASDAQ:GNPX - US3724462037 - Common Stock

5.77 USD
-0.5 (-7.97%)
Last: 10/31/2025, 8:00:01 PM
5.79 USD
+0.02 (+0.35%)
After Hours: 10/31/2025, 8:00:01 PM
Fundamental Rating

2

GNPX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While GNPX seems to be doing ok healthwise, there are quite some concerns on its profitability. GNPX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year GNPX has reported negative net income.
GNPX had a negative operating cash flow in the past year.
In the past 5 years GNPX always reported negative net income.
In the past 5 years GNPX always reported negative operating cash flow.
GNPX Yearly Net Income VS EBIT VS OCF VS FCFGNPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -518.59%, GNPX is doing worse than 96.63% of the companies in the same industry.
GNPX has a worse Return On Equity (-1320.11%) than 82.21% of its industry peers.
Industry RankSector Rank
ROA -518.59%
ROE -1320.11%
ROIC N/A
ROA(3y)-300.81%
ROA(5y)-201.57%
ROE(3y)-614.27%
ROE(5y)-390.18%
ROIC(3y)N/A
ROIC(5y)N/A
GNPX Yearly ROA, ROE, ROICGNPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

GNPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNPX Yearly Profit, Operating, Gross MarginsGNPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

4

2. Health

2.1 Basic Checks

GNPX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GNPX has been increased compared to 5 years ago.
GNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNPX Yearly Shares OutstandingGNPX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K
GNPX Yearly Total Debt VS Total AssetsGNPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -10.29, we must say that GNPX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.29, GNPX is not doing good in the industry: 73.03% of the companies in the same industry are doing better.
There is no outstanding debt for GNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.29
ROIC/WACCN/A
WACCN/A
GNPX Yearly LT Debt VS Equity VS FCFGNPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.83 indicates that GNPX may have some problems paying its short term obligations.
The Current ratio of GNPX (0.83) is worse than 88.95% of its industry peers.
A Quick Ratio of 0.83 indicates that GNPX may have some problems paying its short term obligations.
With a Quick ratio value of 0.83, GNPX is not doing good in the industry: 88.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
GNPX Yearly Current Assets VS Current LiabilitesGNPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. Growth

3.1 Past

GNPX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.49%.
EPS 1Y (TTM)2.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-252.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GNPX will show a very strong growth in Earnings Per Share. The EPS will grow by 36.77% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.94%
EPS Next 2Y36.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNPX Yearly Revenue VS EstimatesGNPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 50M 100M 150M
GNPX Yearly EPS VS EstimatesGNPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800 -1K

1

4. Valuation

4.1 Price/Earnings Ratio

GNPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GNPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNPX Price Earnings VS Forward Price EarningsGNPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNPX Per share dataGNPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as GNPX's earnings are expected to grow with 36.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.77%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for GNPX!.
Industry RankSector Rank
Dividend Yield N/A

GENPREX INC

NASDAQ:GNPX (10/31/2025, 8:00:01 PM)

After market: 5.79 +0.02 (+0.35%)

5.77

-0.5 (-7.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners1.74%
Inst Owner Change0%
Ins Owners0.21%
Ins Owner Change-0.72%
Market Cap247.59M
Revenue(TTM)N/A
Net Income(TTM)-21388400
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-75.79%
Min EPS beat(2)-189.09%
Max EPS beat(2)37.52%
EPS beat(4)1
Avg EPS beat(4)-55.47%
Min EPS beat(4)-189.09%
Max EPS beat(4)37.52%
EPS beat(8)2
Avg EPS beat(8)-39.29%
EPS beat(12)4
Avg EPS beat(12)-26.12%
EPS beat(16)6
Avg EPS beat(16)-17.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4900%
EPS NQ rev (3m)-4900%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 152.82
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.38
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.04
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -518.59%
ROE -1320.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-300.81%
ROA(5y)-201.57%
ROE(3y)-614.27%
ROE(5y)-390.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z -10.29
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)236.4%
Cap/Depr(5y)318.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-252.3%
EPS Next Y85.94%
EPS Next 2Y36.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.68%
OCF growth 3YN/A
OCF growth 5YN/A

GENPREX INC / GNPX FAQ

What is the ChartMill fundamental rating of GENPREX INC (GNPX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNPX.


What is the valuation status of GENPREX INC (GNPX) stock?

ChartMill assigns a valuation rating of 1 / 10 to GENPREX INC (GNPX). This can be considered as Overvalued.


How profitable is GENPREX INC (GNPX) stock?

GENPREX INC (GNPX) has a profitability rating of 0 / 10.


Can you provide the financial health for GNPX stock?

The financial health rating of GENPREX INC (GNPX) is 4 / 10.